Table 2:
AML-associated oncofusion proteins
| Chromosomal translocation | Oncofusion protein | Occurrence (% of AML) | Prognosis | FAB |
|---|---|---|---|---|
| t(8;21)(q22;q22) | AML1–ETO | 5–12 | Favorable | M2 |
| t(15;17)(q22;q21) | PML–RARα | 6–15 | Favorable | M3 |
| inv(16)(p13q22) | CBFβ–MYH11 | 3–10 | Favorable | M4 |
| der(11q23) | MLL-fusions | 5–8 | Variable | M4/M5 |
| t(9;22)(q34;q11) | BCR–ABL1 | 1–2 | Adverse | M1/M2 |
| t(6;9)(p22;q34) | DEK–NUP214 | <1 | Adverse | M2/M4 |
| t(1;22)(p13;q13) | RBM15–MKL1 | <1 | Intermediate | M7 |
| t(8;16)(p11;p13) | MYST3–CREBBP | <1 | Adverse | M4/M5 |
| t(7;11)(p15;p15) | NUP98–HOXA9 | <1 | Intermediate | M2/M4 |
| t(12;22)(p12;q11) | MN1–TEL | <1 | Variable | M4/M7 |
| inv(3)(q21;q26) | RPN1–EVI1 | <1 | Adverse | M1/M2/M4/M6/M7 |
| t(16;21)(p11;q22) | FUS–ERG | <1 | Adverse | M1/M2/M4/M5/M7 |